COVID-19 vaccine - AJ Vaccines

At a glance

Originator AJ Vaccines
Class COVID-19 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research COVID 2019 infections

Most Recent Events

06 Mar 2020 Early research in COVID-2019 infections (Prevention) in Denmark (Parenteral)
06 Mar 2020 AJ Vaccines announces intention to launch COVID-2019 vaccine in 2021

Development Overview

Introduction

COVID-19 vaccine is being developed by AJ Vaccines for prevention against the coronavirus (COVID-19) infections. The company is utilising its modern antigen technology that allows for the production of vaccines combining high protection with a low reactogenicity and favourable safety profile as compared with some of the more traditional vaccines. Early research is underway in Denmark.

Key Development Milestones

In March 2020, AJ Vaccines announced intention to launch COVID-2019 vaccine in 2021^[1].

Drug Properties & Chemical Synopsis

Route of administration Parenteral
Formulation unspecified
Class COVID-19 vaccines
Mechanism of Action Immunostimulants
WHO ATC code
J07B (Viral Vaccines)
EPhMRA code
J7E (Viral Vaccines)

Biomarker

Drug Name	Biomarker Function
COVID-19 vaccine - AJ Vaccines	ACE2	Outcome Measure
	AMH	Detailed Description, Outcome Measure
	Apolipoprotein H antibodies	Eligibility Criteria
	B-cell lymphoma 2 (Bcl-2)	Arm Group Description
	B-lymphocyte antigen CD19	Arm Group Label
	B-lymphocyte antigen CD20	Arm Group Description, Brief Title, Official Title
	Bilirubin	Eligibility Criteria
	C-reactive protein (CRP)	Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure
	C1QL1	Outcome Measure
	Calprotectin	Detailed Description
	Cardiac Troponin I	Eligibility Criteria, Outcome Measure
	CGA	Eligibility Criteria
	chorionic gonadotropin beta subunit 5	Eligibility Criteria
	corticotropin releasing hormone	Outcome Measure
	Cytokeratin 20	Arm Group Description
	D-dimer	Eligibility Criteria
	D-Urobilinogen	Eligibility Criteria
	Estradiol-17beta 3-sulfate	Outcome Measure
	Ferritin	Eligibility Criteria, Outcome Measure
	Ferrocytochrome	Eligibility Criteria
	Fibrinogen	Eligibility Criteria
	FSH	Eligibility Criteria
	fuzzy planar cell polarity protein	Outcome Measure
	GNPTAB	Eligibility Criteria
	Gut Microbiome	Brief Title, Official Title
	heat shock 27kDa protein 3	Outcome Measure
	hypertrichosis 2 (generalized, congenital)	Eligibility Criteria
	immunoglobulin heavy constant epsilon	Outcome Measure
	Insulin	Brief Summary, Outcome Measure
	Interferon alpha (IFN-alpha)	Outcome Measure
	Interferon Gamma (IFNg)	Brief Summary, Detailed Description, Outcome Measure
	Interleukin-2 (IL-2)	Outcome Measure
	Interleukin-4 (IL-4)	Outcome Measure
	Interleukin-5 (IL-5)	Outcome Measure
	Interleukin-6 (IL-6)	Eligibility Criteria, Outcome Measure
	KRT88P	Eligibility Criteria
	L-Lactic acid	Eligibility Criteria
	mutated in colorectal cancers	Brief Summary
	PCNA	Arm Group Label
	PD-1/CD279	Eligibility Criteria, Outcome Measure
	PD-L1/CD274	Brief Title, Eligibility Criteria, Official Title, Outcome Measure
	Phosphonoacetate	Outcome Measure
	Progesterone	Brief Summary, Detailed Description, Outcome Measure
	Protein S	Outcome Measure
	protein tyrosine phosphatase, non-receptor type 6	Eligibility Criteria
	Protoporphyrin IX	Eligibility Criteria
	pyrroline-5-carboxylate reductase 1	Outcome Measure
	RBP4	Outcome Measure
	serine peptidase inhibitor, Kunitz type 1	Outcome Measure
	serine racemase	Outcome Measure
	seryl-tRNA synthetase	Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure
	Soluble transferrin receptor	Outcome Measure
	suppression of tumorigenicity 14 (colon carcinoma)	Outcome Measure
	T-box 1	Eligibility Criteria
	T-Cell differentiation antigen CD8	Detailed Description, Outcome Measure
	T-cell surface antigen CD4	Detailed Description, Eligibility Criteria, Outcome Measure
	TF	Outcome Measure
	Thromboxane	Outcome Measure
	Toll-Like Receptor 4 (TLR4)	Outcome Measure
	Tumor necrosis factor alpha (TNF-alpha)	Outcome Measure
	Vitamin A	Outcome Measure
	vitronectin	Arm Group Description, Arm Group Label, Detailed Description, Official Title, Outcome Measure
	Y Chromosome	Eligibility Criteria
	zinc finger protein 415	Arm Group Description

Development Status

Summary Table

Download Data (CSV)

Indication	Qualifier	Patient Segment	Phase	Countries	Route / Formulation	Developers	Event Date
COVID 2019 infections	-	Prevention	Research	Denmark	Parenteral / unspecified	AJ Vaccines	06 Mar 2020

Commercial Information

Involved Organisations

Organisation	Involvement	Countries
AJ Vaccines	Originator	Malaysia
AJ Vaccines	Owner	Malaysia

Future Events

Expected Date	Event Type	Description	Updated
31 Dec 2021	Regulatory Status	AJ Vaccines announces intention to launch COVID-2019 vaccine in 2021 ^[1]	17 Mar 2020

Development History

Event Date	Update Type	Comment
17 Jan 2022	Biomarker Update	Biomarkers information updated Updated 20 Jan 2022
06 Mar 2020	Phase Change	Early research in COVID-2019 infections (Prevention) in Denmark (Parenteral) ^[1] Updated 17 Mar 2020
06 Mar 2020	Regulatory Status	AJ Vaccines announces intention to launch COVID-2019 vaccine in 2021 ^[1] Updated 17 Mar 2020

Welcome to AdisInsight